Nanotech Boom Presents Challenges For Both Industry, Regulators
This article was originally published in The Tan Sheet
Executive Summary
FDA says it stands ready to shepherd the nanotech industry into producing safe and effective nanotech-based OTC drugs, cosmetics and other products despite gaps that exist in its ability to regulate the technology as it develops
You may also be interested in...
Nanotech Experts Question Whether Regulatory “Gaps” Affect Consumers
Nanotechnology experts, speaking at a meeting organized for FDA's Internal Nanotechnology Task Force, debated whether gaps in FDA's regulation of the technology actually represent problems for the industry and consumers
FDA Nanotechnology Oversight Limited By Budget Constraints – Report
FDA's budget constraints and gaps in its legal authority hinder its ability to understand and manage nanotechnology's potential risks, according to Michael Taylor, professor at the University of Maryland School of Medicine and former FDA deputy commissioner for policy
Task Force To Develop Approaches To Nanotechnology In Drugs, Foods
FDA's Nanotechnology Task Force will identify policy gaps related to the use of nanotechnology particles to evaluate possible adverse health effects from products that contain the materials, the agency said